Pfizer gained a bidding struggle to get the GLP-1 drug that’s the cornerstone of its cardiometabolic drug pipeline. Now the pharmaceutical firm has as much as $1.5 billion to fund assessments of that peptide in weight problems and different associated indications.
The money will come from Blackstone Life Sciences. In alternate for the financing, the deal introduced after Wednesday’s market shut makes the funding agency eligible for milestone funds tied to the regulatory progress and potential commercialization of the drug, berobenatide. Monetary particulars concerning the milestones weren’t disclosed, however given the dimensions of the cardiometabolic illness market, these funds could possibly be substantial.
Berobenatide was the lead weight problems drug candidate of Metsera, the place it was identified by the code identify MET-097i. This long-acting injectable GLP-1 drug was designed for month-to-month dosing, making it engaging to Novo, which has been on the lookout for a successor to its weekly injectable GLP-1 weight problems drug, Wegovy. Pfizer’s inner analysis in oral GLP-1 medicine had fallen brief, sparking its personal seek for exterior belongings. A couple of yr in the past, Pfizer beat out Novo with a $10 billion supply for Metsera that now provides the pharma firm one other alternative in metabolic medicines.
Pfizer is evaluating berobenatide in a broad scientific program that the corporate says may develop to greater than 20 trials in weight problems and associated comorbidities, comparable to knee osteoarthritis and obstructive sleep apnea. Pfizer additionally says the rising physique of proof helps advancing growth of the peptide a monotherapy and together with numerous nutrient-stimulated hormone (NuSH) peptides, together with analogs for amylin, a hormone within the physique that performs a task in regulating blood sugar and urge for food. The Pfizer cardiometabolic pipeline additionally contains an oral GLP-1 drug acquired final yr from Shanghai-based YaoPharma.
Within the announcement of the Blackstone deal, Pfizer Chief Monetary Officer and Govt Vice President Cecile Guegan mentioned the corporate is taking “a disciplined method that pairs inner analysis investments with focused funding from capital companions.”
“As we speak’s announcement helps us advance our complete weight problems program and preserve the monetary capability and adaptability to spend money on our broader pipeline throughout all therapeutic areas,” Guegan mentioned.
Novo and Eli Lilly, at the moment the leaders in peptide medicine for weight problems, have gone on to safe regulatory approvals in associated indications. Novo’s Wegovy can be utilized to deal with the fatty liver illness MASH; Wegovy tablet’s approval for weight administration contains use of the drug as approach to scale back the danger of main cardiovascular occasions. In the meantime, Lilly’s Zepbound has added obstructive sleep apnea to its label.
Whereas Pfizer touts much less burdensome month-to-month dosing of berobenatide, Lilly’s method to next-generation metabolic drugs goals for higher efficacy. Retatrutide, a Lilly peptide engineered to activate the GLP-1, GIP, and glucagon receptors, is in a broad scientific trial program evaluating the drug in each weight problems and sort 2 diabetes together with associated problems.
Blackstone has reached financing offers with different biopharmaceutical firms. Earlier this yr, the agency agreed to offer Apogee Therapeutics with as much as $1.3 billion to assist late-stage scientific growth of its long-acting antibody drug for atopic dermatitis. In alternate, Blackstone could be entitled to royalties from gross sales of an authorised product. Apogee was subsequently acquired by AbbVie for about $11 billion. Blackstone’s agreements with Moderna and Alnylam Prescription drugs put the funding agency in line for milestone funds and royalties.
Beneath the phrases of the Pfizer/Blackstone deal, funds managed by Blackstone’s perpetual non-public fairness technique will make investments alongside funds managed by Blackstone Life Sciences. If berobenatide achieves milestones, milestone funds will probably be paid out over a multi-year interval. The funding agency doesn’t acquire any rights to the drug; Pfizer maintains full management of the asset and all selections concerning the scientific program.
Photograph: Getty Photos
